The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer.

ABSTRACT: Zinc-dependent histone deacetylases (HDACs) are pivotal enzymes governing the epigenetic modulation of gene expression through chromatin remodeling. The dysregulated expression of HDACs is intricately linked to various pathological conditions, including cancer and inflammation. Histone deacetylase inhibitors (HDACi) have shown therapeutic potential in certain hematologic malignancies. However, the clinical performance of HDACi in solid tumors remains unsatisfactory, and the precise mechanisms of its therapeutic effect in solid tumors has not been fully elucidated. In this study, we identified nucleus-localized PFKL (Liver-type phosphofructokinase), as a key regulator of HDACi efficacy and intracellular epigenetic dynamics. Nuclear PFKL directly binds to class I HDACs through interacting wi

SUBMITTER: Shang T 

PROVIDER: S-EPMC12518634 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature